Table 2.
Sample characteristics: Baseline and chemotherapy data. Patient n=244.
| Variable | |
|---|---|
| Age, years, median (range) | 75 (70–91) |
| Female gender, N (%) | 156 (63.9) |
| Tumor site, N (%) | |
| Breast | 101 (41.4) |
| Non Hodgkin’s lymphoma | 33 (13.5) |
| Colorectal | 23 (9.4) |
| Lung | 17 (7.1) |
| Prostate | 15 (6.1) |
| Other | 55 (22.5) |
| Metastatic disease stage, N(%) | 125 (51.2) |
| Number of medications, median (range) | 11.5 (3 – 41) |
| BMI, kg/m2 mean (SD) | 26.4 (4.9) |
| Blood pressure, mm Hg mean (SD) | 138 (22)/74 (10) |
| ECOG PS, N(%) | |
| 0 | 127 (52.0) |
| 1 | 80 (32.8) |
| 2 | 30 (12.3) |
| 3 | 7 (2.9) |
| Baseline | |
| Albumin, g/dL (SD) | 3.7 (0.4) |
| Bilirubin, mg/dL (SD) | 0.5 (0.2) |
| AST, U/L (SD) | 32.4 (18.8) |
| Creatinine clearance, mL/min (SD) | 63.9 (22.9) |
| RBC count, 106/μL (SD) | 4.1 (0.6) |
| MAX2, mean (SD) | 0.62 (0.17) |
| Grade 3–4 non-hematological toxicity, % | 126 (51.6) |
| Grade 4 hematological toxicity, % | 66 (27.0) |
Notes: Results are means and SD unless otherwise indicated. Abbreviations: BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group performance status; AST, aspartate aminotransferase; RBC, red blood cell.